Cite
HARVARD Citation
Dignass, A. et al. (n.d.). A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL. Journal of the Canadian Association of Gastroenterology. pp. 29-31. [Online].